Endocrine Functions of Bone Are Suppressed by Orally Administered Glucose Regardless of Bodyweight
Authors' conclusion
Osteokines respond rapidly to oral glucose regardless of body weight. Orally-administered glucose affects not only bone turnover but can also suppress bone endocrine functions. Furthermore, obesity may influence the effect of oral glucose on circulating levels of bone turnover markers.
Study context
- Population
- Participants with normal weight or obesity, age 21–54 yr
- Participants
- 22 vs 27
- Comparison
- Normal weight vs obesity: osteokine response to oral glucose tolerance test (OGTT)
- Normal weightn = 22reference
- Obesityn = 27
- Outcome
- Change in circulating osteokines (b-CTX-I, total OC, sclerostin, cFGF23, uncarboxylated OC, LCN2) after OGTT
- Follow-up
- Baseline and 2 h
Main finding
As reported in the abstract
Osteokine and bone turnover marker responses to OGTT · 2 h
- Median decrease in b-CTX-I, both groups (p < 0.0001)
- 42%
- Osteocalcin (OC) decrease, both groups (p < 0.0001)
- 11%
- FGF23 decrease, both groups (p = 0.007)
- 14%
- Uncarboxylated OC decrease, only in obesity (p < 0.0001)
- 1.2%
- Sclerostin decrease, only in obesity (p = 0.032)
- 7.8%
Original publication
Endocrine Functions of Bone Are Suppressed by Orally Administered Glucose Regardless of Bodyweight. Clin Endocrinol (Oxf). Published 24 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →